Recapitulating dengue virus infection with human pluripotent stem cell-derived liver organoids for antiviral screening

Meng-Qi Li, Yan-Peng Xu, Kai Li, Chao Zhou, Xiao-Xuan Fan, Hui Wang, Pan-Deng Shi, Rui-Ting Li, Zu-Xin Wang, Tian-Shu Cao, Qi Chen, Yu-Jun Cui, Yong-Qiang Deng, Xiao-Yan Wu, Hui Zhao () and Cheng-Feng Qin ()
Additional contact information
Meng-Qi Li: Academy of Military Medical Sciences
Yan-Peng Xu: Capital Medical University, Capital Institute of Pediatrics
Kai Li: Academy of Military Medical Sciences
Chao Zhou: Academy of Military Medical Sciences
Xiao-Xuan Fan: Academy of Military Medical Sciences
Hui Wang: Academy of Military Medical Sciences
Pan-Deng Shi: Academy of Military Medical Sciences
Rui-Ting Li: Academy of Military Medical Sciences
Zu-Xin Wang: Academy of Military Medical Sciences
Tian-Shu Cao: Academy of Military Medical Sciences
Qi Chen: Academy of Military Medical Sciences
Yu-Jun Cui: Academy of Military Medical Sciences
Yong-Qiang Deng: Academy of Military Medical Sciences
Xiao-Yan Wu: Academy of Military Medical Sciences
Hui Zhao: Academy of Military Medical Sciences
Cheng-Feng Qin: Academy of Military Medical Sciences

Nature Communications, 2025, vol. 16, issue 1, 1-18

Abstract: Abstract Dengue virus (DENV) poses a major global health threat, affecting an estimated 100 to 400 million people annually. The infection and pathogenesis remain incompletely understood, and no antiviral drug is currently approved for DENV treatment. Here, we develop a human pluripotent stem cell (hPSC)-derived liver organoid (hPLO) model to characterize DENV infection and screen for antivirals. The hPLOs, containing various liver cell types, are highly susceptible to DENV-2 infection, resulting in severe cell death and morphological changes that mimic the pathology observed in severe dengue cases. Single-cell RNA sequencing (scRNA-seq) of DENV-2 infected hPLOs reveals that proliferating hepatocyte-like cells are the primary target cells of DENV-2, with significant mitochondrial damage and alterations in cell-type composition. Further drug screening in hPLOs identifies oxyresveratrol (Oresveratrol, ORES) and omaveloxolone (RTA 408) as potent anti-DENV candidates. These compounds enhance resistance to DENV-2 infection by activating the NRF2 pathway, reducing oxidative stress, and preserving mitochondrial function. The efficacy of ORES and RTA 408 is further validated in the established AG6 mouse model. Our study not only establishes hPLOs as a valuable platform for studying DENV infection and pathogenesis, but also highlights the vital role of NRF2-mediated mitochondrial function for antiviral development.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-63323-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63323-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-63323-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().